Analysts Anticipate Pacira Biosciences Inc (NASDAQ:PCRX) Will Announce Quarterly Sales of $120.21 Million

Equities analysts predict that Pacira Biosciences Inc (NASDAQ:PCRX) will announce sales of $120.21 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Pacira Biosciences’ earnings, with the lowest sales estimate coming in at $118.30 million and the highest estimate coming in at $124.00 million. Pacira Biosciences posted sales of $95.12 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 26.4%. The company is expected to announce its next quarterly earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Pacira Biosciences will report full year sales of $418.88 million for the current financial year, with estimates ranging from $416.90 million to $423.00 million. For the next financial year, analysts expect that the company will post sales of $497.37 million, with estimates ranging from $477.54 million to $527.34 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Pacira Biosciences.

Pacira Biosciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.35. Pacira Biosciences had a return on equity of 10.19% and a net margin of 0.55%. The firm had revenue of $104.69 million during the quarter, compared to the consensus estimate of $104.88 million. During the same quarter in the prior year, the company earned $0.31 EPS. The business’s revenue for the quarter was up 25.5% on a year-over-year basis.

A number of research firms recently issued reports on PCRX. BidaskClub upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Barclays boosted their target price on shares of Pacira Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. BMO Capital Markets dropped their target price on shares of Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating on the stock in a research note on Friday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $56.00 target price on shares of Pacira Biosciences in a research report on Thursday, November 7th. Finally, Jefferies Financial Group set a $60.00 price target on shares of Pacira Biosciences and gave the stock a “buy” rating in a research note on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. Pacira Biosciences has a consensus rating of “Hold” and an average target price of $52.55.

In other news, VP Lauren Bullaro Riker sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $43.59, for a total value of $217,950.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David M. Stack sold 70,000 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $44.47, for a total transaction of $3,112,900.00. Over the last ninety days, insiders have sold 76,176 shares of company stock worth $3,382,759. Insiders own 5.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Usca Ria LLC bought a new stake in shares of Pacira Biosciences during the 3rd quarter valued at $38,000. HM Payson & Co. bought a new position in Pacira Biosciences in the 2nd quarter worth about $39,000. C M Bidwell & Associates Ltd. bought a new position in Pacira Biosciences in the 2nd quarter worth about $44,000. LS Investment Advisors LLC purchased a new position in Pacira Biosciences during the 3rd quarter valued at about $50,000. Finally, Tower Research Capital LLC TRC grew its holdings in Pacira Biosciences by 414.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after buying an additional 1,157 shares in the last quarter. Institutional investors own 99.13% of the company’s stock.

NASDAQ PCRX opened at $46.04 on Wednesday. The business’s fifty day moving average is $42.18 and its 200-day moving average is $41.19. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.95 and a quick ratio of 3.32. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 158.76, a PEG ratio of 2.07 and a beta of 1.17. Pacira Biosciences has a one year low of $34.64 and a one year high of $50.30.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on Pacira Biosciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.